Home / Resources / Annual Completed Clinical Trials: By the Numbers

Annual Completed Clinical Trials: By the Numbers

Infographic
Clinical
''

Completed clinical trials continued to climb in 2024 at an even faster pace.

According to Trialtrove, 4,903 industry-sponsored clinical studies from Phase I through Phase III/IV either reached completed status or attained primary endpoints during 2024.

This is a 14.2% jump from 2023 totals, higher than the 10.7% rise recorded from 2022 to 2023 and the greatest increase in the last eight years.

Download the infographic to learn more.


Related products
Professional using a laptop device to access Trialtrove for trial insights and strategy.
Trialtrove
The go-to resource for informing clinical trial strategy, design and execution
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape
Digital map showcasing the reach of Sitetrove, providing data from trial sites across the globe.
Sitetrove
The industry-leading suite of global clinical trial investigator and site intelligence

Related resources

''
APR 15, 2025
Webinar
Clinical

Pharma R&D Review 2025

Watch on-demand our expert trendspotters as they explore the latest global drug development trends, highlight companies making bold statements in R&D, and reveal which therapeutic categories are en vogue right now.

The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery
OCT 02, 2024
White paper
Clinical

The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery

The 2024 Clinical Trials Round focuses on Phase I–III clinical trials that initiated in 2023 across all therapeutic areas covered by Citeline’s Trialtrove.

Woman looking at the screen with a graph
MAR 26, 2025
White paper
Clinical

Smarter Trials, Stronger Outcomes: Using Proprietary Data to Gain a Competitive Edge

To keep pace in today’s highly competitive market, sponsors must leverage proprietary data that reveal details on site and investigator performance.

View all